Reuters logo
BRIEF-Novartis' Lucentis receives EU approval in new indication
December 7, 2016 / 6:23 AM / a year ago

BRIEF-Novartis' Lucentis receives EU approval in new indication

Dec 7 (Reuters) - Novartis

* Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions

* The European Commission approved Lucentis to treat patients for visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular degeneration (nAMD) or secondary to pathologic myopia (PM)

* Results of the pivotal MINERVA study showed a significant gain in visual acuity of approximately 10 letters at two months, which was maintained for one year Further company coverage: (Reporting by Brenna Hughes Neghaiwi)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below